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Background: Few data are available on the procoagulant microparticles (MPs) at the site of the culprit plaque in acute myocardial infarction 
(AMI). In this study, we investigated the levels and cellular origins of MPs in the aspirate from the culprit coronary artery of patients with AMI.
Methods: In this study, we studied 21 patients with AMI (17 men, age 60 ± 15) who underwent primary angioplasty (PCI), and 16 control patients 
(9 men, age 62 ± 10) who underwent coronary angiography with non-coronary disease. Blood sample from the femoral artery was obtained prior to 
PCI, and at the end of PCI. Sampling of aspirate from the culprit coronary arteries was performed using the Export aspiration catheter before and 
after PCI. In control group, only peripheral blood from the femoral artery was obtained after angiography. MPs were isolated by capture with annexin 
A5 and determined their procoagulant potential with a prothrombinase assay using commercial kit. The cell origins of MPs were determined by 
antigenic capture with specific antibodies.
Results: Baseline MPs with procoagulant potential in patients with AMI were higher than in control group (16.1 ± 18.1 vs. 3.9 ± 5.7 nM 
phosphatidylserine (PS) equivalent, P=0.008). Especially, levels of platelet derived CD42b+ MPs were significantly elevated in patients with AMI 
compared with control (P=0.010). The level of procoagulant MPs did not differ significantly between culprit coronary artery and peripheral artery, 
regardless of their cellular origins. However, pre-intervention MPs from peripheral artery were significantly reduced after PCI (16.1 ± 18.1 vs. 10.6 
± 16.6 nM PS equivalent, P=0.005). Restoration of the epicardial blood flow led to a significant reduction of endothelial cell derived CD146+ MPs 
within the culprit coronary artery and platelet derived CD42b+ MPs in peripheral artery, respectively.
Conclusions: The level of procoagulant MPs did not differ significantly between culprit coronary artery and peripheral artery. However, high levels 
of procoagulant platelet MPs in the circulating blood and significant reduction of their levels after successful PCI suggest their pathophysiological 
role in AMI.
